Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 58 articles:
HTML format
Text format



Single Articles


    November 2018
  1. JIN H, Ko YS, Kim HJ
    P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer.
    Int J Oncol. 2018;53:1953-1966.
    PubMed     Text format     Abstract available


  2. PIZON M, Schott DS, Pachmann U, Pachmann K, et al
    B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
    Int J Oncol. 2018;53:2289-2299.
    PubMed     Text format     Abstract available


    October 2018
  3. KIM SK, Kim K, Ryu JW, Ryu TY, et al
    The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.
    Int J Oncol. 2018 Oct 26. doi: 10.3892/ijo.2018.4608.
    PubMed     Text format     Abstract available


  4. FURLAN A, Vercamer C, Heliot L, Wernert N, et al
    Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells.
    Int J Oncol. 2018 Oct 24. doi: 10.3892/ijo.2018.4605.
    PubMed     Text format     Abstract available


  5. TAN Y, Wang Q, Xie Y, Qiao X, et al
    Identification of FOXM1 as a specific marker for triplenegative breast cancer.
    Int J Oncol. 2018 Oct 19. doi: 10.3892/ijo.2018.4598.
    PubMed     Text format     Abstract available


  6. GAO Y, Liu H, Wang H, Hu H, et al
    Baicalin inhibits breast cancer development via inhibiting IkB kinase activation in vitro and in vivo.
    Int J Oncol. 2018 Oct 12. doi: 10.3892/ijo.2018.4594.
    PubMed     Text format     Abstract available


  7. LU H, Chen J, Luo Y, Xu H, et al
    Curcolonol suppresses the motility of breast cancer cells by inhibiting LIM kinase 1 to downregulate cofilin 1 phosphorylation.
    Int J Oncol. 2018 Oct 10. doi: 10.3892/ijo.2018.4592.
    PubMed     Text format     Abstract available


  8. SHAO YC, Nie XC, Song GQ, Wei Y, et al
    Prognostic value of DKK2 from the Dickkopf family in human breast cancer.
    Int J Oncol. 2018 Oct 9. doi: 10.3892/ijo.2018.4588.
    PubMed     Text format     Abstract available


    September 2018
  9. ZHAO Y, Pang W, Yang N, Hao L, et al
    MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway.
    Int J Oncol. 2018 Sep 27. doi: 10.3892/ijo.2018.4576.
    PubMed     Text format     Abstract available


  10. SUN L, He M, Xu N, Xu DH, et al
    Regulation of RAB22A by mir-193b inhibits breast cancer growth and metastasis mediated by exosomes.
    Int J Oncol. 2018 Sep 25. doi: 10.3892/ijo.2018.4571.
    PubMed     Text format     Abstract available


    August 2018
  11. LI B, Chen P, Wang J, Wang L, et al
    MicroRNA-1254 exerts oncogenic effects by directly targeting RASSF9 in human breast cancer.
    Int J Oncol. 2018 Aug 21. doi: 10.3892/ijo.2018.4530.
    PubMed     Text format     Abstract available


  12. GAO Z, Wang H, Li H, Li M, et al
    Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway.
    Int J Oncol. 2018 Aug 13. doi: 10.3892/ijo.2018.4522.
    PubMed     Text format     Abstract available


    July 2018
  13. LIU J, Li X, Wang M, Xiao G, et al
    A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Int J Oncol. 2018 Jul 19. doi: 10.3892/ijo.2018.4492.
    PubMed     Text format     Abstract available


  14. LIU F, Sang M, Meng L, Gu L, et al
    miR92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2.
    Int J Oncol. 2018 Jul 18. doi: 10.3892/ijo.2018.4486.
    PubMed     Text format     Abstract available


  15. LIU Y, Dong Y, Zhao L, Su L, et al
    Circular RNAMTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis.
    Int J Oncol. 2018 Jul 17. doi: 10.3892/ijo.2018.4485.
    PubMed     Text format     Abstract available


  16. WANG Y, Yan L, Zhang L, Xu H, et al
    NT21MP negatively regulates paclitaxel-resistant cells by targeting miR1553p and miR155-5p via the CXCR4 pathway in breast cancer.
    Int J Oncol. 2018 Jul 9. doi: 10.3892/ijo.2018.4477.
    PubMed     Text format     Abstract available


  17. WU CL, Zhang SM, Lin L, Gao SS, et al
    BECN1-knockout impairs tumor growth, migration and invasion by suppressing the cell cycle and partially suppressing the epithelial-mesenchymal transition of human triple-negative breast cancer cells.
    Int J Oncol. 2018 Jul 5. doi: 10.3892/ijo.2018.4472.
    PubMed     Text format     Abstract available


  18. JIMENEZ-MORALES S, Perez-Amado CJ, Langley E, Hidalgo-Miranda A, et al
    Overview of mitochondrial germline variants and mutations in human disease: Focus on breast cancer (Review).
    Int J Oncol. 2018 Jul 4. doi: 10.3892/ijo.2018.4468.
    PubMed     Text format     Abstract available


  19. DONG H, Wang W, Chen R, Zhang Y, et al
    Exosome-mediated transfer of lncRNASNHG14 promotes trastuzumab chemoresistance in breast cancer.
    Int J Oncol. 2018 Jul 3. doi: 10.3892/ijo.2018.4467.
    PubMed     Text format     Abstract available


  20. FRISTIOHADY A, Milovanovic D, Krieger S, Huttary N, et al
    12(S)-HETE induces lymph endothelial cell retraction in vitro by upregulation of SOX18.
    Int J Oncol. 2018;53:307-316.
    PubMed     Text format     Abstract available


    June 2018
  21. HAN W, Cao F, Gao XJ, Wang HB, et al
    ZIC1 acts a tumor suppressor in breast cancer by targeting survivin.
    Int J Oncol. 2018 Jun 21. doi: 10.3892/ijo.2018.4450.
    PubMed     Text format     Abstract available


  22. NOWAK A, Dziegiel P
    Implications of nestin in breast cancer pathogenesis (Review).
    Int J Oncol. 2018 Jun 14. doi: 10.3892/ijo.2018.4441.
    PubMed     Text format     Abstract available


  23. CARLISLE SM, Hein DW
    Retrospective analysis of estrogen receptor 1 and Nacetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.
    Int J Oncol. 2018 Jun 11. doi: 10.3892/ijo.2018.4436.
    PubMed     Text format     Abstract available


    May 2018
  24. CHENG CC, Shi LH, Wang XJ, Wang SX, et al
    Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Int J Oncol. 2018 May 8. doi: 10.3892/ijo.2018.4399.
    PubMed     Text format     Abstract available


  25. KIM JY, Kim JC, Lee JY, Park MJ, et al
    Oct4 suppresses IRinduced premature senescence in breast cancer cells through STAT3- and NFkappaB-mediated IL24 production.
    Int J Oncol. 2018 May 2. doi: 10.3892/ijo.2018.4391.
    PubMed     Text format     Abstract available


    April 2018
  26. TAN Y, Zhou G, Wang X, Chen W, et al
    USP18 promotes breast cancer growth by upregulating EGFR and activating the AKT/Skp2 pathway.
    Int J Oncol. 2018 Apr 30. doi: 10.3892/ijo.2018.4387.
    PubMed     Text format     Abstract available


  27. ZHAO Y, Onda K, Yuan B, Tanaka S, et al
    Arsenic disulfideinduced apoptosis and its potential mechanism in two and threedimensionally cultured human breast cancer MCF7 cells.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4357.
    PubMed     Text format     Abstract available


    March 2018
  28. ZHAO FQ, Misra Y, Li DB, Wadsworth MP, et al
    Differential expression of Oct3/4 in human breast cancer and normal tissues.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4341.
    PubMed     Text format     Abstract available


  29. XIONG DD, Chen H, He RQ, Lan AH, et al
    MicroRNA-671-3p inhibits the development of breast cancer: A study based on in vitro experiments, in-house quantitative polymerase chain reaction and bioinformatics analysis.
    Int J Oncol. 2018 Mar 28. doi: 10.3892/ijo.2018.4339.
    PubMed     Text format     Abstract available


  30. COLIN C, Meyer M, Cerella C, Kleinclauss A, et al
    Biotinylation enhances the anticancer effects of 15dPGJ2 against breast cancer cells.
    Int J Oncol. 2018 Mar 28. doi: 10.3892/ijo.2018.4338.
    PubMed     Text format     Abstract available


  31. BUSCHMANN D, Gonzalez R, Kirchner B, Mazzone C, et al
    Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer.
    Int J Oncol. 2018 Mar 27. doi: 10.3892/ijo.2018.4336.
    PubMed     Text format     Abstract available


  32. LI Y, Zhang Y, Liu X, Wang M, et al
    Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1.
    Int J Oncol. 2018 Mar 23. doi: 10.3892/ijo.2018.4332.
    PubMed     Text format     Abstract available


  33. WU T, Song H, Xie D, Zhao B, et al
    Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.
    Int J Oncol. 2018 Mar 20. doi: 10.3892/ijo.2018.4331.
    PubMed     Text format     Abstract available


  34. BEBEROK A, Wrzesniok D, Rok J, Rzepka Z, et al
    Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway.
    Int J Oncol. 2018 Mar 8. doi: 10.3892/ijo.2018.4310.
    PubMed     Text format     Abstract available


  35. DI D, Chen L, Guo Y, Wang L, et al
    BCSC-1 suppresses human breast cancer metastasis by inhibiting NF-kappaB signaling.
    Int J Oncol. 2018 Mar 7. doi: 10.3892/ijo.2018.4309.
    PubMed     Text format     Abstract available


  36. MIYAGAWA Y, Matsushita Y, Suzuki H, Komatsu M, et al
    Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4301.
    PubMed     Text format     Abstract available


  37. WANG H, Xiao Y, Wu L, Ma D, et al
    Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis.
    Int J Oncol. 2018;52:743-754.
    PubMed     Text format     Abstract available


    February 2018
  38. CASTELLANOS-ESPARZA YC, Wu S, Huang L, Buquet C, et al
    Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells.
    Int J Oncol. 2018 Feb 9. doi: 10.3892/ijo.2018.4272.
    PubMed     Text format     Abstract available


  39. MAXWELL T, Lee KS, Kim S, Nam KS, et al
    Arctigenin inhibits the activation of the mTOR pathway, resulting in autophagic cell death and decreased ER expression in ER-positive human breast cancer cells.
    Int J Oncol. 2018 Feb 9. doi: 10.3892/ijo.2018.4271.
    PubMed     Text format     Abstract available


  40. HAN Y, Fan S, Qin T, Yang J, et al
    Role of autophagy in breast cancer and breast cancer stem cells (Review).
    Int J Oncol. 2018 Feb 8. doi: 10.3892/ijo.2018.4270.
    PubMed     Text format     Abstract available


  41. YEN MC, Huang YC, Kan JY, Kuo PL, et al
    S100B expression in breast cancer as a predictive marker for cancer metastasis.
    Int J Oncol. 2018;52:433-440.
    PubMed     Text format     Abstract available


  42. NOWAK A, Grzegrzolka J, Kmiecik A, Piotrowska A, et al
    Role of nestin expression in angiogenesis and breast cancer progression.
    Int J Oncol. 2018;52:527-535.
    PubMed     Text format     Abstract available


    January 2018
  43. PENG F, Li Q, Sun JY, Luo Y, et al
    PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis.
    Int J Oncol. 2018 Jan 30. doi: 10.3892/ijo.2018.4257.
    PubMed     Text format     Abstract available


  44. ZHONG R, Liang B, Xin R, Zhu X, et al
    Deoxycytidine kinase participates in the regulation of radiation-induced autophagy and apoptosis in breast cancer cells.
    Int J Oncol. 2018 Jan 22. doi: 10.3892/ijo.2018.4250.
    PubMed     Text format     Abstract available


  45. YOU KS, Yi YW, Kwak SJ, Seong YS, et al
    Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    Int J Oncol. 2018 Jan 15. doi: 10.3892/ijo.2018.4244.
    PubMed     Text format     Abstract available


  46. ABSMAIER M, Napieralski R, Schuster T, Aubele M, et al
    PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Int J Oncol. 2018 Jan 8. doi: 10.3892/ijo.2018.4241.
    PubMed     Text format     Abstract available


  47. CHANG LC, Hsieh MT, Yang JS, Lu CC, et al
    Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.
    Int J Oncol. 2018;52:67-76.
    PubMed     Text format     Abstract available


  48. WANG Y, Yu X, Song H, Feng D, et al
    The STAT-ROS cycle extends IFNinduced cancer cell apoptosis.
    Int J Oncol. 2018;52:305-313.
    PubMed     Text format     Abstract available


    November 2017
  49. ALONSO-GONZALEZ C, Menendez-Menendez J, Gonzalez-Gonzalez A, Gonzalez A, et al
    Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF7 human breast cancer cells.
    Int J Oncol. 2017 Nov 28. doi: 10.3892/ijo.2017.4213.
    PubMed     Text format     Abstract available


  50. SONNENBLICK A, Salgado R, Brohee S, Zahavi T, et al
    p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.
    Int J Oncol. 2017 Nov 27. doi: 10.3892/ijo.2017.4212.
    PubMed     Text format     Abstract available


    October 2017
  51. RAMAN V, Fuentes Lorenzo JL, Stashenko EE, Levy M, et al
    Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-kappaB signaling in triple-negative breast cancer cells.
    Int J Oncol. 2017 Oct 19. doi: 10.3892/ijo.2017.4169.
    PubMed     Text format     Abstract available


  52. BORAH N, Gunawardana S, Torres H, McDonnell S, et al
    5,6,7,3',4',5'-Hexamethoxyflavone inhibits growth of triple-negative breast cancer cells via suppression of MAPK and Akt signaling pathways and arresting cell cycle.
    Int J Oncol. 2017 Oct 13. doi: 10.3892/ijo.2017.4157.
    PubMed     Text format     Abstract available


  53. RATAJCZAK-WIELGOMAS K, Grzegrzolka J, Piotrowska A, Matkowski R, et al
    Expression of periostin in breast cancer cells.
    Int J Oncol. 2017;51:1300-1310.
    PubMed     Text format     Abstract available


  54. YIN H, Zhu Q, Liu M, Tu G, et al
    GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.
    Int J Oncol. 2017;51:1191-1198.
    PubMed     Text format     Abstract available


  55. PHILLIPS SL, Williams CB, Zambrano JN, Williams CJ, et al
    Connexin 43 in the development and progression of breast cancer: What's the connection? (Review).
    Int J Oncol. 2017;51:1005-1013.
    PubMed     Text format     Abstract available


    September 2017
  56. YANG L, Li Y, Shen E, Cao F, et al
    NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Int J Oncol. 2017 Sep 21. doi: 10.3892/ijo.2017.4130.
    PubMed     Text format     Abstract available


  57. ESPINOZA-SANCHEZ NA, Vadillo E, Balandran JC, Monroy-Garcia A, et al
    Evidence of lateral transmission of aggressive features between different types of breast cancer cells.
    Int J Oncol. 2017 Sep 19. doi: 10.3892/ijo.2017.4128.
    PubMed     Text format     Abstract available


  58. CALAF GM, Roy D
    Metastatic genes targeted by an antioxidant in an established radiation- and estrogen-breast cancer model.
    Int J Oncol. 2017 Sep 14. doi: 10.3892/ijo.2017.4125.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: